HC Wainwright Analysts Give Nektar Therapeutics (NKTR) a $125.00 Price Target

HC Wainwright set a $125.00 price objective on Nektar Therapeutics (NASDAQ:NKTR) in a research note released on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

NKTR has been the topic of a number of other reports. Zacks Investment Research raised shares of Nektar Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 21st. BidaskClub downgraded shares of Nektar Therapeutics from a strong-buy rating to a buy rating in a research note on Thursday, February 8th. Mizuho upped their price target on shares of Nektar Therapeutics from $89.00 to $103.00 and gave the stock a buy rating in a research note on Friday, April 6th. Jefferies Group upped their price target on shares of Nektar Therapeutics to $103.00 and gave the stock a buy rating in a research note on Friday, March 2nd. Finally, Canaccord Genuity upped their price target on shares of Nektar Therapeutics to $94.00 and gave the stock a buy rating in a research note on Friday, March 2nd. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $66.91.

NASDAQ NKTR opened at $102.77 on Monday. Nektar Therapeutics has a 1-year low of $17.33 and a 1-year high of $111.36. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. The firm has a market capitalization of $16,808.40, a PE ratio of -186.85 and a beta of 1.74.



Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.14. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The business had revenue of $95.47 million for the quarter, compared to the consensus estimate of $36.96 million. During the same period in the prior year, the business posted ($0.28) earnings per share. Nektar Therapeutics’s revenue for the quarter was up 154.9% compared to the same quarter last year. sell-side analysts predict that Nektar Therapeutics will post -1.33 EPS for the current year.

In other Nektar Therapeutics news, SVP Maninder Hora sold 20,000 shares of the stock in a transaction on Thursday, April 5th. The shares were sold at an average price of $101.75, for a total transaction of $2,035,000.00. Following the transaction, the senior vice president now directly owns 127,394 shares of the company’s stock, valued at $12,962,339.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $75.82, for a total transaction of $6,318,308.06. Following the transaction, the chief executive officer now directly owns 333,268 shares in the company, valued at $25,268,379.76. The disclosure for this sale can be found here. Insiders have sold 574,592 shares of company stock worth $53,470,081 over the last three months. Company insiders own 5.44% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NKTR. Nationwide Fund Advisors increased its position in Nektar Therapeutics by 67.2% during the third quarter. Nationwide Fund Advisors now owns 179,877 shares of the biopharmaceutical company’s stock worth $4,317,000 after buying an additional 72,322 shares during the last quarter. Legal & General Group Plc boosted its holdings in Nektar Therapeutics by 3.9% during the third quarter. Legal & General Group Plc now owns 306,478 shares of the biopharmaceutical company’s stock valued at $7,348,000 after acquiring an additional 11,475 shares during the period. Wells Fargo & Company MN boosted its holdings in Nektar Therapeutics by 5.0% during the third quarter. Wells Fargo & Company MN now owns 215,561 shares of the biopharmaceutical company’s stock valued at $5,174,000 after acquiring an additional 10,189 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Nektar Therapeutics by 7.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 703,282 shares of the biopharmaceutical company’s stock valued at $16,879,000 after acquiring an additional 48,435 shares during the period. Finally, Allianz Asset Management GmbH boosted its holdings in Nektar Therapeutics by 7.4% during the third quarter. Allianz Asset Management GmbH now owns 108,409 shares of the biopharmaceutical company’s stock valued at $2,602,000 after acquiring an additional 7,507 shares during the period. 96.22% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Analysts Give Nektar Therapeutics (NKTR) a $125.00 Price Target” was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://dakotafinancialnews.com/2018/04/12/hc-wainwright-analysts-give-nektar-therapeutics-nktr-a-125-00-price-target.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply